Anticoagulants News
-
CD Formulation Unveils Prominent Pharmaceutical Ingredients and Excipients for Enhanced Medicine Efficacy
In the quest to develop safe and effective medicines, pharmaceutical companies rely on the precise combination of active pharmaceutical ingredients (APIs) and excipients. These crucial components play a pivotal role in the formulation of pharmaceutical drugs, ensuring optimal drug delivery and patient outcomes. Recently, CD Formulation released a comprehensive guide titled "Active Pharmaceutical ...
-
Expanding Possibilities: CD Formulation Unveils Comprehensive Selection of 90+ Active Pharmaceutical Ingredients
Emerging as an excipient supplier and a contract research organization (CRO), CD Formulation has flourished in the pharmaceutical industry. The company recently unveiled its latest collection of over 90 active pharmaceutical ingredients (APIs) to the scientific community. These APIs will serve as essential components in the formulation of various drugs. APIs are the primary components of ...
-
Online Sales of Prescription Drugs via Donation
Many public services, e.g. the public school system, make up resource deficits by soliciting or accepting private charitable donations. This strategy does not work for prescription drug donations as they require a medical order for sale to a private customer; a prospective donor can’t simply walk into Walgreens and buy epinephrine, heparin, insulin, Zofran, Dilaudid or ketamine. Emergency ...
-
CD BioGlyco Released Separation of Glycosaminoglycans Service Recently
CD BioGlyco, a biotechnology company that provides glycobiology-related products, analysis, custom synthesis, and design to advance glycobiology research, recently announced the release of separation of Separation of Glycosaminoglycans service to the science community. Glycosaminoglycans, once known as mucopolysaccharides, are mainly found in the connective tissues of higher animals and plants. ...
By CD BioGlyco.
-
CD Bioparticles Launches Heparins for Drug Delivery Research
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of Heparins products to support drug delivery research, such as the Heparin Biotin, Heparin Amine, and Heparin Thiol. Researchers can choose Heparins by molecular weight such as 27 kDa, or by functional groups such as Biotin, Amine and Thiol. For example, Heparin Biotin ...
-
Valeo Pharma Obtains Public Reimbursement For Redesca And Redesca Hp In Quebec
Public reimbursement coverage reaches 9 Provinces in Canada Canadian private health plan coverage now exceeding 90% Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Quebec Minister of Health, for ...
-
First-in-Human Trial Evaluates Safety and Efficacy of Rex Medical`s Large Bore Closer System
November 7, 2018 — At VIVA 2018, the Vascular Interventional Advances annual conference held November 5–8 in Las Vegas, Nevada, Micah Watts, MD, presented findings from the first-in-human clinical trial of the Large Bore Closer vascular sealing system (Rex Medical). The trial evaluated 23 patients at a single site and assessed the safety and effectiveness of the Large Bore Closer ...
-
EMOSIS reinforces its Intellectual Property and scientific expertise
The French innovative Medical Device start-up Emosis, specializing in cytomolecular diagnostics of thrombosis and hemostasis disorders, is reinforcing its intellectual property on HIT Confirm®, Emosis first test kit which was recently launched in Europe (CE Mark). The company was granted a US patent “Platelet Analysis System” (US10, 012,658 B2), and the PCT of the patent ...
-
Transluminal Technologies completes the First-in-Man study of the velox LB vascular closure device
Asuncion, Paraguay, April 20, 2017 – Transluminal Technologies, LLC, a Syracuse, NY-based medical device company has announced today that they have successfully completed the First-in-Man clinical study of the velox LB large bore vascular closure device with 100% procedural success (10/10). Methods: Patients with a baseline common femoral artery (CFA) diameter of ≥ 6.0 mm were ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you